CoChat

Do proton pump inhibitors alter the response to immune checkpoint inhibitors in cancer patients? A meta-analysis

Open access

The DOI matches its Crossref record; 86 of the 86 references it cites were found in a registry or an index.

Abstract

Introduction: Gut microbiota can significantly affect the effectiveness of immune checkpoint inhibitors (ICIs) in cancer patients. Recently, antibiotics were shown to decrease survival rate of patients treated by ICIs. Proton pump inhibitors (PPIs) can indeed modulate microbiota’s diversity, therefore altering ICIs response. A meta-analysis was performed based on published data to verify this hypothesis. Methods: In this study, over 41 publications, exploring the impact of concomitant PPI treatment on outcomes of ICI-treated patients, were analyzed. Evaluated endpoints were overall survival (OS) and progression-free survival (PFS). Pooled hazard ratios (HRs) with a 95% confidence interval (CI) were reported in ICIs in PPI users versus non-PPI users. Subgroup analyses were performed to minimize the impact of study heterogeneity and to investigate the influence of PPI on the different groups of interest. There was no evidence of publication bias for OS and PFS analysis in subgroup analysis. Results: Forty-one studies were included in the meta-analysis, including a total of 20,042 patients. OS of patients receiving ICIs was negatively correlated in patients concomitantly treated with PPI (HR=1.37; 95%CI, 1.23–1.52). PFS of cancer patients receiving ICIs was also negatively correlated with PPI treatment (HR=1.28; 95%CI, 1.15–1.42). PPI and ICI use was associated with worst OS and PFS not only for non-small-cell lung cancer (NSCLC) or urothelial cancer patients but also for patients treated with anti PD-1 (OS) and anti PD-L1 (OS and PFS) immunotherapies when administered in non-first line and when PPI was received as baseline treatment or in 60 days before ICI initiation. PPI and ICI use also showed the worst OS and PFS for patients from Europe and Asia. Conclusion: This meta-analysis suggests that PPI treatment leads to significantly worse outcomes in advanced cancer patients treated by ICIs in terms of PFS and OS.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fimmu.2023.1070076

Cites

86 of 86 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) flow diagram of articles identification and selection. PPI, proton pump inhibitor.
Figure 1 Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) flow diagram of articles identification and selection. PPI, proton pump inhibitor.CC BY · PubMed Central
Figure 2 Association between PPI use and overall survival (A) and progression-free survival (B) in cancer patients treated with immunotherapy. PPI, proton pump inhibitor; CI, confidence interval.
Figure 2 Association between PPI use and overall survival (A) and progression-free survival (B) in cancer patients treated with immunotherapy. PPI, proton pump inhibitor; CI, confidence interval.CC BY · PubMed Central
Figure 3 Begg’s funnel plot of HR ratios of (A) OS and (B) PFS. HR, hazard ratio; SE, standard error.
Figure 3 Begg’s funnel plot of HR ratios of (A) OS and (B) PFS. HR, hazard ratio; SE, standard error.CC BY · PubMed Central
Figure 4 Subgroup analysis of association between PPI use and overall survival by (A) cancer type, (B) type of immunotherapy, (C) treatment line, (D) PPIs use window, and (E) continents. PPI, proton pump inhibitor; CI, confidence interval; NSCLC, non-small cell lung cancer; ICI, immune checkpoint inhibitor.
Figure 4 Subgroup analysis of association between PPI use and overall survival by (A) cancer type, (B) type of immunotherapy, (C) treatment line, (D) PPIs use window, and (E) continents. PPI, proton pump inhibitor; CI, confidence interval; NSCLC, non-small cell lung cancer; ICI, immune checkpoint inhibitor.CC BY · PubMed Central
Figure 5 Subgroup analysis of association between PPI use and progression-free survival by (A) cancer type, (B) type of immunotherapy, (C) treatment line, (D) PPIs use window, and (E) by continents. PPI, proton pump inhibitor; CI, confidence interval; NSCLC, non-small cell lung cancer; ICI, immune checkpoint inhibitor.
Figure 5 Subgroup analysis of association between PPI use and progression-free survival by (A) cancer type, (B) type of immunotherapy, (C) treatment line, (D) PPIs use window, and (E) by continents. PPI, proton pump inhibitor; CI, confidence interval; NSCLC, non-small cell lung cancer; ICI, immune checkpoint inhibitor.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 86 references

Research works printed but not linked: 2

  1. Wells, 2009, The Newcastle-Ottawa scale (NOS) for assessing the quality if nonrandomized studies in meta-analyses
  2. Hossain, 2020, Immunotherapy efficacy and concomitant proton pump inhibitor use in non-small cell lung cancer, Asia Pac J Clin Oncol, 16, 37

Cited by

See all 79

Metadata

Authors
Lopes, S., Pabst, L., Dory, A., Klotz, M., Gourieux, B., Michel, B., & Mascaux, C.
Affiliations
  • Hôpitaux Universitaires de Strasbourg (FR)
  • Inserm (FR)
Corresponding author
Mascaux, Céline
Venue
Frontiers in Immunology
Published
2023-01-26
Volume
14
Pages
1070076-1070076
ISSN
1664-3224 (ISSN-L)
OpenAlex
W4318049653
Cited by
75
References
85
Citations by year
2026: 28 · 2025: 24 · 2024: 14 · 2023: 9
FWCI
2.43
Type
journal article
Language
en
Open access
Locations
  • Frontiers in Immunology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Ferroptosis and cancer prognosis
Keywords
proton pump inhibitors, immune checkpoint inhibitors, gut microbiota, cancer immunotherapy, overall survival, progression-free survival, non-small cell lung cancer, urothelial carcinoma, anti-PD-1 therapy, PD-L1 blockade, antibiotic use, drug-drug interactions
MeSH terms
Immune Checkpoint Inhibitors, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Humans, Lung Neoplasms, Proton Pump Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Do proton pump inhibitors alter the response to immune checkpoint inhibitors in cancer patients? A meta-analysis. https://app.cochat.ai/papers/10.3389/fimmu.2023.1070076
The paper
Lopes, S., Pabst, L., Dory, A., Klotz, M., Gourieux, B., Michel, B., & Mascaux, C. (2023). Do proton pump inhibitors alter the response to immune checkpoint inhibitors in cancer patients? A meta-analysis. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2023.1070076

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.